---
document_datetime: 2023-09-21 17:20:02
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/fasturtec-epar-all-authorised-presentations_en.pdf
document_name: fasturtec-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7631468
conversion_datetime: 2025-12-19 04:03:48.641656
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength   | Pharmaceutical Form                                          | Route of Administration   | Immediate Packaging           | Content (concentration)                   | Pack size            |
|------------------|-------------------|------------|--------------------------------------------------------------|---------------------------|-------------------------------|-------------------------------------------|----------------------|
| EU/1/00/170/001  | Fasturtec         | 1.5 mg/ml  | Powder and solvent for concentrate for solution for infusion | Intravenous use           | vial (glass); ampoule (glass) | powder: 1.5 mg; solvent: 1 ml (1.5 mg/ml) | 3 vials + 3 ampoules |
| EU/1/00/170/002  | Fasturtec         | 1.5 mg/ml  | Powder and solvent for concentrate for solution for infusion | Intravenous use           | vial (glass); ampoule (glass) | powder: 7.5 mg; solvent: 5 ml (1.5 mg/ml) | 1 vial + 1 ampoule   |